{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:58:48Z","timestamp":1788026328193,"version":"build-2784847793"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Japan Tobacco Inc."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previous studies demonstrated that delgocitinib ointment, a novel topical Janus kinase inhibitor, rapidly improved clinical signs and symptoms of atopic dermatitis (AD) in Japanese adult patients. We sought to evaluate the long\u2010term safety and efficacy of delgocitinib 0.5% ointment in a 52\u2010week study (QBA4\u20102). Japanese patients aged 16\u00a0years or older with AD received delgocitinib 0.5% ointment b.i.d. for up to 52\u00a0weeks. Topical corticosteroids for the treatment of worsening of AD could be used at the investigators\u2019 discretion during the treatment period. Safety end\u2010points included the incidence and severity of adverse events (AEs). Pooled safety analyses included the data from the other long\u2010term study (QBA4\u20101). Efficacy end\u2010points included the percentage change from baseline in the modified Eczema Area and Severity Index (mEASI). A total of 506 patients were included in the pooled safety population. Overall, AEs were reported in 69.0% of patients; most AEs were mild and unrelated to delgocitinib ointment. The most common AE was nasopharyngitis, followed by\u00a0contact dermatitis, acne, and application site folliculitis. No skin atrophy or telangiectasia was found at the application sites of delgocitinib ointment. Application site irritation symptoms were infrequent (&lt;2%) and mild. The incidence of AEs did not increase over time, except for seasonal diseases. The improvement effects on AD as assessed by mEASI were maintained throughout the treatment period. Delgocitinib 0.5% ointment was well tolerated and effective when administrated to Japanese adult patients with AD for up to 52\u00a0weeks.<\/jats:p>","DOI":"10.1111\/1346-8138.15173","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T04:59:20Z","timestamp":1575953960000},"page":"114-120","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Long\u2010term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis"],"prefix":"10.1111","volume":"47","author":[{"given":"Hidemi","family":"Nakagawa","sequence":"first","affiliation":[{"name":"The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Kojinkai Sapporo Skin Clinic Hokkaido Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology NTT Medical Center Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-0355","authenticated-orcid":false,"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nippon Medical School Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusei","family":"Murata","sequence":"additional","affiliation":[{"name":"Pharmaceutical Division Japan Tobacco Inc. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Kaino","sequence":"additional","affiliation":[{"name":"Pharmaceutical Division Japan Tobacco Inc. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3300-7922","authenticated-orcid":false,"given":"Takeshi","family":"Nagata","sequence":"additional","affiliation":[{"name":"Pharmaceutical Division Japan Tobacco Inc. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13392"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.12.003"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.023"},{"key":"e_1_2_7_5_1","unstructured":"Eucrisa (crisaborol)[prescribing information].New York NY:Pfizer Inc;2018. [Cited 28 November 2019.] Available from URL:http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?xml:id=5331."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-014-0782-9"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.014"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.10.045"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21060"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-012-8264-z"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxy015"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011040"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.07.012"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.10.033"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13370"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.03.051"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.02.556"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14322"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16014"},{"key":"e_1_2_7_20_1","unstructured":"Clinicaltrials.jp.Phase III clinical study of JTE\u2010052 Ointment \u2010 randomized controlled and long\u2010term extension study of JTE\u2010052 Ointment in patients with atopic dermatitis \u2010 [JapicCTI\u2010173554]. [Cited 28 November 2019.] Available from URL:https:\/\/www.clinicaltrials.jp\/cti-user\/trial\/Search.jsp(publication in preparation)."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2001.100102.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.11.002"},{"key":"e_1_2_7_23_1","unstructured":"Clinicaltrials.jp.Phase III clinical study of JTE\u2010052 ointment \u2010 randomized controlled and long\u2010term extension study of JTE\u2010052 ointment in Japanese Pediatric Patients with Atopic Dermatitis \u2010 [JapicCTI\u2010184064]. [Cited 28 November 2019.] Available from URL:https:\/\/www.clinicaltrials.jp\/cti-user\/trial\/Search.jsp."}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.15173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.15173","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:32:49Z","timestamp":1693290769000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.15173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1111\/1346-8138.15173"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.15173","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,9]]},"assertion":[{"value":"2019-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}